| Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure 2002 · acetylcysteine group · Adults with chronic renal insufficiency undergoing a coronary procedure; age and sex not stated | 800 mg | — | 60 |
| Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies 2012 · G2, pancreatic cancer · Adults aged 18–65 with unresectable locally advanced pancreatic adenocarcinoma | 800 mg | 8 weeks | 30 |
| Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies 2012 · G2, non-small-cell lung cancer · Adults aged 18–65 with unresectable locally advanced non-small-cell lung cancer | 800 mg | 8 weeks | 30 |
| Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies 2012 · G2, hormone-refractory metastatic prostate cancer · Men aged 18–65 with hormone-refractory metastatic prostate cancer | 800 mg | 8 weeks | 30 |
| N-acetylcysteine Restored Heart Rate Variability and Prevented Serious Adverse Events in Transfusion-dependent Thalassemia Patients: a Double-blind Single Center Randomized Controlled Trial 2020 · NAC group · Adults aged 18–50 with transfusion-dependent thalassemia | 600 mg | 26 weeks | 30 |
| N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD 1999 · standard therapy plus NAC · Patients with moderate to severe COPD | 600 mg | 26 weeks | — |
| Effect of oral N-acetyl cysteine on recurrent preterm labor following treatment for bacterial vaginosis 2009 · NAC group · Pregnant women at 16–18 weeks with one previous preterm birth, recently treated successfully for bacterial vaginosis | 600 mg | — | — |
| Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial 2014 · N-acetylcysteine group · Adults aged 40–80 years with moderate-to-severe COPD | 1.2 g | 1 year | 504 |
| Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study 2019 · NAC · Adults with chronic obstructive pulmonary disease; smoking status varied | 1.2 g | — | 482 |
| N-Acetyl cysteine and clomiphene citrate for induction of ovulation in polycystic ovary syndrome: a cross-over trial 2007 · clomiphene citrate plus N-acetyl cysteine · Women with polycystic ovary syndrome | 1.2 g | 5 days | 470 |
| Effect of high-dose N-acetylcysteine on exacerbations and lung function in patients with mild-to-moderate COPD: a double-blind, parallel group, multicentre randomised clinical trial 2024 · N-acetylcysteine group · Adults aged 40–80 with mild-to-moderate COPD (GOLD stage 1–2) | 1.2 g | 88 weeks | 464 |
| Effect of N-acetylcysteine against Vancomycin-Induced Nephrotoxicity: A Randomized Controlled Clinical Trial 2020 · drug (NAC) group · Patients receiving vancomycin for any indication | 1.2 g | 10 days | 84 |
| Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial 2019 · N-acetylcysteine group · Adults aged 18–80 with idiopathic or post-infective bronchiectasis and at least two exacerbations in the past year, stable for at least 4 weeks before randomisation | 1.2 g | 1 year | 81 |
| Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial 2022 · NAC prophylaxis cohort (group A) · Patients aged 15–60 years with acute leukemia in complete remission undergoing first haploidentical HSCT and pre-HSCT bone-marrow endothelial cell percentage <0.1% | 1.2 g | 12 weeks | 80 |
| N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate-resistant patients with polycystic ovary syndrome 2005 · NAC group (group I) · Women aged 18–39 with clomiphene citrate-resistant PCOS undergoing infertility therapy | 1.2 g | 5 days | 75 |
| N-acetylcysteine versus N-acetylcysteine + theophylline for the prevention of contrast nephropathy 2009 · Group 2 · Patients with eGFR 30–60 mL/min/1.73 m² undergoing coronary angiography | 1.2 g | 2 days | 73 |
| N-acetylcysteine versus N-acetylcysteine + theophylline for the prevention of contrast nephropathy 2009 · Group 3 · Patients with eGFR 30–60 mL/min/1.73 m² undergoing coronary angiography | 1.2 g | 2 days | 72 |
| The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial 2003 · acetylcysteine group · Adults with end-stage renal failure undergoing maintenance hemodialysis; mean age 62 years, 76 male and 58 female across the trial | 1.2 g | 63 weeks | 64 |
| Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD 2014 · NAC · Chinese adults with spirometry-confirmed stable COPD; mean age 70.8 years; 93.2% men | 1.2 g | 1 year | 52 |
| Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine 2000 · acetylcysteine group · Patients with chronic renal insufficiency undergoing computed tomography with a nonionic, low-osmolality contrast agent | 1.2 g | — | 41 |
| Does nebivolol prevent contrast-induced nephropathy in humans? 2012 · Group I · Patients scheduled for coronary angiography and ventriculography; age and sex not reported | 1.2 g | 4 days | 40 |
| Effect of N-acetyl-cysteine after ovarian drilling in clomiphene citrate-resistant PCOS women: a pilot study 2010 · group A · women with clomiphene citrate-resistant polycystic ovary syndrome who underwent unilateral laparoscopic ovarian drilling | 1.2 g | 5 days | 30 |
| Effect of antioxidant therapy on hospital stay and complications in patients with early acute pancreatitis: a randomised controlled trial 2009 · SMT + AO · Adults admitted within 72 hours of onset of pain with acute pancreatitis; age and sex not specified | 600 mg | — | 23 |
| Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results 2008 · N-acetylcysteine (NAC) · Patients with moderately impaired kidney function receiving low-osmolar, non-ionic contrast media | 1.2 g | 2 days | 19 |
| Safety and efficacy of N-acetylcysteine in hospitalized patients with HIV-associated tuberculosis: An open-label, randomized, phase II trial (RIPENACTB Study) 2020 · NAC Group · Adults aged 18 years or older, any gender, hospitalized with HIV-associated pulmonary tuberculosis | 1.2 g | 8 weeks | 18 |
| [N-acetylcystein in the therapy of chronic bronchitis] 2002 · NAC added to standard antibiotic therapy · Patients with acute exacerbation of chronic bronchitis and positive bacterial culture in sputum; mean age 66 years; 16 male and 8 female | 1.2 g | — | — |
| Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography 2003 · acetylcysteine · Patients with serum creatinine ≥1.5 mg/dL undergoing cardiac catheterization, with mild to moderate renal impairment | 1.2 g | — | — |
| Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity 2004 · Standard-dose group (SD Group) · Patients with chronic renal insufficiency undergoing contrast-agent procedures | 1.2 g | — | — |
| Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial 2007 · Sodium chloride plus oral NAC · Patients with baseline creatinine >1.2 mg/dL undergoing cardiovascular procedures | 1.2 g | — | — |
| N-Acetylcysteine as an adjuvant to clomiphene citrate for successful induction of ovulation in infertile patients with polycystic ovary syndrome 2012 · group 1 (CC+NAC) · Infertile patients with polycystic ovary syndrome; age and sex not specified | 1.2 g | 5 days | — |
| A double-blinded, placebo-controlled, multicenter clinical trial of N-acetylcysteine for preventing amphotericin B-induced nephrotoxicity 2015 · N-acetylcysteine (NAC) · Patients receiving amphotericin B treatment | 1.2 g | — | — |
| Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study 2009 · N-acetyl-cysteine group · Infertile men with idiopathic oligo-asthenoteratospermia | 600 mg | 26 weeks | 118 |
| Effects of N-acetylcysteine on semen parameters and oxidative/antioxidant status 2009 · study group · men with idiopathic infertility | 600 mg | 90 days | 60 |
| Effects of N-acetyl-cysteine supplementation on sperm quality, chromatin integrity and level of oxidative stress in infertile men 2019 · NAC treatment · Men aged 25–40 years with infertility and terato-asthenozoospermia | 600 mg | 90 days | 50 |
| N-acetylcysteine versus placebo for treating nail biting, a double blind randomized placebo controlled clinical trial 2013 · NAC group · Children and adolescents with chronic nail biting | 800 mg | 60 days | 21 |
| Preventing cisplatin induced ototoxicity by N-acetylcysteine and salicylate 2010 · N-acetylcysteine group · Adults with solid organ tumors receiving cisplatin chemotherapy; mean age 37 years, range 29–71; both sexes | 600 mg | — | 18 |
| A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis 2009 · 700 mg NAC (low-dose) · Patients older than 16 years with cystic fibrosis and stable disease | 700 mg | 12 weeks | 11 |
| N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study 2008 · group A · Patients with mild to moderate ulcerative colitis; age and sex not specified | 800 mg | 4 weeks | — |
| N-acetylcysteine supplementation improves endocrine-metabolism profiles and ovulation induction efficacy in polycystic ovary syndrome 2024 · NAC group · Women aged 21–38 with PCOS and anovulation or oligo-ovulation undergoing ovulation induction | 1.8 g | 5 days | 115 |
| N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up 2004 · N-acetylcysteine (NAC) · Patients with moderate renal dysfunction undergoing PCI or coronary angiography with a high likelihood of ad hoc PCI | 4 g | 1 day | 95 |
| Adjunctive N-Acetylcysteine and Lung Function in Pulmonary Tuberculosis 2024 · standard therapy with NAC · Adults with moderate or far-advanced pulmonary tuberculosis | 2.4 g | 16 weeks | 70 |
| N-acethyl-cysteine reduces the occurrence of contrast-induced acute kidney injury in patients with renal dysfunction: a single-center randomized controlled trial 2013 · SN group · Patients with renal dysfunction undergoing diagnostic-therapeutic procedures with low-osmolar contrast media | 1.2 g | 2 days | 38 |
| N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial 2016 · Group A · High-risk patients undergoing elective cardiac catheterization | 2.4 g | — | 30 |
| Effects of antioxidants on glutathione levels and clinical recovery from the malnutrition syndrome kwashiorkor--a pilot study 2005 · N-acetylcysteine group · Children with severe kwashiorkor | 200 mg | 20 days | — |
| N-acetylcysteine in Acute Organophosphorus Pesticide Poisoning: A Randomized, Clinical Trial 2016 · N-acetylcysteine group · Patients with acute organophosphorus pesticide poisoning; age and sex not specified | 1.8 g | 3 days | — |
| A randomized, double-blind, placebo-controlled study evaluating the efficacy of propolis and N-acetylcysteine in exacerbations of chronic obstructive pulmonary disease 2022 · AS-1,200 · Patients with frequent-exacerbation COPD following an acute exacerbation | 1.2 g | 90 days | — |
| N-Acetylcysteine as Prophylactic Therapy for Transplantation-Associated Thrombotic Microangiopathy: A Randomized, Placebo-Controlled Trial 2022 · oral NAC · Patients scheduled for allogeneic hematopoietic stem cell transplantation | 50 mg/kg | 39 days | — |
| Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study 2009 · selenium plus N-acetyl-cysteine group · Infertile men with idiopathic oligo-asthenoteratospermia | 600 mg | 26 weeks | 116 |
| N-acetylcysteine improves the clinical conditions of mustard gas-exposed patients with normal pulmonary function test 2008 · group 1 (N-acetylcysteine) · Patients with bronchiolitis obliterans due to sulfur mustard exposure and bronchiolitis obliterans syndrome class 0 | 1.2 g | 120 days | 72 |
| Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis 1994 · NAC · Patients with mild chronic bronchitis; age and sex not reported | 1.2 g | 22 weeks | 59 |
| Fluoxetine versus N-acetylcysteine in reducing craving in Indian men with alcohol dependence syndrome: a randomised controlled trial 2025 · N-acetylcysteine (NAC) · Men aged 18 to 65 years with alcohol dependence syndrome who had maintained at least 7 days of alcohol abstinence | 1.2 g | 12 weeks | 50 |
| [Clinical efficacy of tetrandrine combined with acetylcysteine effervescent tablets in treatment of silicosis] 2013 · treatment group · Adults with silicosis; age and sex not reported | 1.2 g | — | 49 |
| Effects of N-acetylcysteine supplementation on disease activity, oxidative stress, and inflammatory and metabolic parameters in rheumatoid arthritis patients: a randomized double-blind placebo-controlled trial 2022 · NAC group · Adults with rheumatoid arthritis; age and sex not specified | 1.2 g | 90 days | 37 |
| The efficacy of N-acetylcysteine in the treatment of methamphetamine dependence: a double-blind controlled, crossover study 2015 · NAC group (crossover supplement phase) · Methamphetamine-dependent volunteers | 1.2 g | 4 weeks | 32 |
| Administration of maximum dose of mucolytic solution before upper endoscopy - a double-blind, randomized trial 2023 · A · Adults over 18 years undergoing diagnostic gastroscopy | 600 mg | 1 day | 30 |
| N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study 2007 · open-label NAC · Adults with DSM-IV pathological gambling; 12 of the 27 participants were women | 1.48 g | 8 weeks | 27 |
| Evaluating the Effect of Oral N-acetylcysteine as an Adjuvant Treatment on Clinical Outcomes of Patients with Rheumatoid Arthritis: A Randomized, Double Blind Clinical Trial 2018 · NAC group · Adults with active rheumatoid arthritis | 1.2 g | 12 weeks | 27 |
| Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study 2009 · NAC treatment · Adults older than 40 years with moderate-to-severe COPD | 1.2 g | 6 weeks | 24 |
| N-acetylcysteine in chronic blepharitis 2002 · therapy group · Patients with chronic posterior blepharitis | 300 mg | 120 days | 22 |
| N-acetylcysteine supplementation controls total antioxidant capacity, creatine kinase, lactate, and tumor necrotic factor-alpha against oxidative stress induced by graded exercise in sedentary men 2011 · NAC supplement group · Healthy, sedentary, nonathletic men aged 20–24 years | 1.2 g | 7 days | 18 |
| Priming of beta-2 agonist and antimuscarinic induced physiological responses induced by 1200mg/day NAC in moderate to severe COPD patients: A pilot study 2014 · NAC treatment · Adults with moderate-to-very severe COPD; age and sex not reported | 1.2 g | 15 days | 15 |
| Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals 2006 · N-acetylcysteine condition · Adults aged 23–45, six males and seven females, with cocaine dependence who were not seeking treatment | 1.2 g | 3 days | 13 |
| Effect of N-acetylcysteine on cycling performance after intensified training 2014 · NAC · Well-trained triathletes undergoing strenuous physical training; age and sex not reported | 1.2 g | 9 days | 10 |
| Influence of n-acetylcysteine maintenance on the pharmacodynamic effects of oral ethanol 2020 · 1.2 g/day n-acetylcysteine condition · Adults aged 21–55 with moderate to severe alcohol use disorder | 1.2 g | 5 days | 9 |
| N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study 2007 · NAC during double-blind phase · Responders with DSM-IV pathological gambling from the open-label phase | 1.48 g | 6 weeks | 6 |
| Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD 2008 · N-acetylcysteine (NAC) · Adults with mild-to-moderate COPD (GOLD class 1–2) who were current smokers with at least 10 pack-years | 1.2 g | 10 days | — |
| Modulatory effect of N-acetylcysteine on pro-antioxidant status and haematological response in healthy men 2010 · NAC · Healthy men; age range not reported | 1.2 g | 9 days | — |
| A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders 2013 · N-Acetylcysteine + risperidone · Children aged 3.5–16 years, both sexes, with autism spectrum disorder | 1.2 g | 8 weeks | — |
| Comparison of the effects of N-acetyl-cysteine and ginseng in prevention of noise induced hearing loss in male textile workers 2014 · Group I · Male textile workers exposed to continuous occupational noise | 1.2 g | 2 weeks | — |
| Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial 2018 · NAC group · Patients with chronic schizophrenia receiving conventional antipsychotic medication; age and sex not specified | 1.2 g | 12 weeks | — |
| Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study 2020 · low dose group · Breast cancer patients receiving adjuvant paclitaxel | 1.2 g | 12 weeks | — |
| Study of the Effects of N-acetylcysteine on Inflammatory Biomarkers and Disease Activity Score in Patients with Rheumatoid Arthritis 2021 · NAC group · Patients with active rheumatoid arthritis; age and sex not reported | 1.2 g | 8 weeks | — |
| Men suffering from category III chronic prostatitis may benefit from N-acetylcysteine as an adjunct to alpha-blockers 2022 · NAC treatment group · Men with category III chronic prostatitis and NIH-CPSI total score of 15 or more | 1.2 g | 12 weeks | — |
| Randomized Clinical Trial of Antioxidant Therapy Patients with Septic Shock and Organ Dysfunction in the ICU: SOFA Score Reduction by Improvement of the Enzymatic and Non-Enzymatic Antioxidant System 2023 · Group 3 (NAC) · Adults older than 18 years of any gender with septic shock admitted to the ICU | 1.2 g | 5 days | — |
| N-Acetyl Cysteine as an Add-on Therapy is Useful in Treating Acute Lumbar Radiculopathy Caused by Disc Herniation: Results of a Randomized, Controlled Clinical Trial 2023 · NAC group · Patients with acute lumbar radiculopathy associated with disc herniation | 1.2 g | 8 weeks | — |
| Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment 1997 · NAC group · Adults of both sexes; 78% were aged 65 years or older, and 62% had nonrespiratory chronic degenerative diseases; people with chronic respiratory diseases were excluded. | 1.2 g | 26 weeks | — |
| N-acetylcysteine and contrast-induced nephropathy in primary angioplasty 2006 · double dose of N-acetylcysteine · Patients with acute myocardial infarction undergoing primary angioplasty | 2.4 g | 2 days | 119 |
| N-acetylcysteine and contrast-induced nephropathy in primary angioplasty 2006 · standard dose of N-acetylcysteine · Patients with acute myocardial infarction undergoing primary angioplasty | 1.2 g | 2 days | 116 |
| N-acethyl-cysteine reduces the occurrence of contrast-induced acute kidney injury in patients with renal dysfunction: a single-center randomized controlled trial 2013 · BN group · Patients with renal dysfunction undergoing diagnostic-therapeutic procedures with low-osmolar contrast media | 1.2 g | 2 days | 43 |
| N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial 2016 · Group B · High-risk patients undergoing elective cardiac catheterization | 1.2 g | — | 30 |
| Interferon/antioxidant combination therapy for chronic hepatitis C--a controlled pilot trial 1999 · group C · Interferon-naive patients with chronic hepatitis C; age and sex not reported | 1.8 mg | 24 weeks | 8 |
| A randomized, double-blind, placebo-controlled study evaluating the efficacy of propolis and N-acetylcysteine in exacerbations of chronic obstructive pulmonary disease 2022 · AS-600 · Patients with frequent-exacerbation COPD following an acute exacerbation | 600 mg | 90 days | — |
| The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial 2011 · open-label NAC treatment phase · Adults with bipolar disorder and moderate depression | 2 g | 8 weeks | 149 |
| The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial 2018 · NAC · Adults aged 18–50 seeking treatment for cannabis dependence; both sexes | 2.4 g | 12 weeks | 142 |
| N-Acetylcysteine for the Treatment of Co-Occurring Posttraumatic Stress Disorder and Alcohol Use Disorder: A Double-Blind, Randomized Controlled Trial 2025 · NAC · Adults aged 21–65 years with current PTSD and alcohol use disorder | 2.4 g | 12 weeks | 93 |
| High-dose acetylcysteine in idiopathic pulmonary fibrosis 2005 · acetylcysteine · Adults with idiopathic pulmonary fibrosis | 1.8 g | 1 year | 92 |
| Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial 2009 · NAC · Adults aged 18–75 with idiopathic pulmonary fibrosis and a histological or radiological pattern typical for usual interstitial pneumonia | 1.8 g | 1 year | 80 |
| Therapeutics effect of N-acetyl cysteine on mustard gas exposed patients: evaluating clinical aspect in patients with impaired pulmonary function test 2008 · Group 1 (NAC) · Patients with bronchiolitis obliterans due to sulfur mustard exposure, in bronchiolitis obliterans syndrome classes 1 and 2 | 1.8 g | 120 days | 72 |
| A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents 2012 · N-acetylcysteine group · Adolescents aged 15–21 with cannabis dependence | 2.4 g | 8 weeks | 58 |
| Alcohol use during a trial of N-acetylcysteine for adolescent marijuana cessation 2016 · NAC group · Participants aged 15–21 with marijuana dependence who used marijuana regularly and were interested in cessation treatment; participants with alcohol dependence were excluded. | 2.4 g | 8 weeks | 45 |
| N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis 2018 · NAC · Men and women aged 18–40 with early psychosis and less than 12 months of treatment for psychosis | 2.7 g | 26 weeks | 31 |
| Baseline serum amino acid levels predict treatment response to augmentation with N-acetylcysteine (NAC) in a bipolar disorder randomised trial 2021 · NAC · Adults with bipolar disorder experiencing a current acute depressive episode | 2 g | 16 weeks | 31 |
| Administration of maximum dose of mucolytic solution before upper endoscopy - a double-blind, randomized trial 2023 · B · Adults over 18 years undergoing diagnostic gastroscopy | 400 mg | 1 day | 30 |
| Cognitive effects of adjunctive N-acetyl cysteine in psychosis 2017 · NAC · Participants with psychosis, including schizophrenia or bipolar disorder; age and sex not reported | 2 g | 24 weeks | 27 |
| Anti-oxidant N-acetylcysteine diminishes diesel exhaust-induced increased airway responsiveness in person with airway hyper-reactivity 2014 · diesel exhaust with N-acetylcysteine · Non-smoking adults, including individuals with baseline airway hyper-responsiveness; exposed to diesel exhaust | 1.8 g | 6 days | 26 |
| N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial 2016 · Fluvoxamine plus NAC · Patients with moderate-to-severe obsessive-compulsive disorder; age and sex not specified | 2 g | 10 weeks | 22 |
| N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study 2013 · NAC · Patients with chronic schizophrenia, in the active phase of illness, with a negative PANSS subscale score of 20 or greater; sex and age not reported | 2 g | 8 weeks | 21 |
| The therapeutic effect of N-acetylcysteine as an add-on to methadone maintenance therapy medication in outpatients with substance use disorders: A randomized, double-blind, placebo-controlled clinical trial 2023 · NAC group · Adults aged 18–60 with substance use disorder receiving methadone maintenance therapy | 2.4 g | 12 weeks | 21 |
| A Double-Blind, Randomized, Controlled Pilot Trial of N-Acetylcysteine in Veterans With Posttraumatic Stress Disorder and Substance Use Disorders 2016 · NAC · Veterans aged 18–65 with current substance use disorder and PTSD or subthreshold PTSD; primarily male | 2.4 g | 8 weeks | 18 |
| N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin 2016 · NAC group · Women aged 25–35 with polycystic ovary syndrome undergoing intracytoplasmic sperm injection | 1.8 g | 6 weeks | 15 |
| N-Acetylcysteine Rinse for Thick Secretion and Mucositis of Head and Neck Chemoradiotherapy (Alliance MC13C2): A Double-Blind Randomized Clinical Trial 2019 · N-acetylcysteine arm · Adults with head and neck cancer undergoing concurrent chemoradiotherapy | 2.5 g | — | 15 |
| The role of cystine-glutamate exchange in nicotine dependence in rats and humans 2009 · N-acetylcysteine · Adults dependent on nicotine, smoking at least 10 cigarettes per day for at least one year, in stable mental and physical health, and seeking to reduce cigarette use | 2.4 g | 4 weeks | 14 |
| Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients 2013 · NAC · Adults aged 40 years or older with moderate COPD, all categorized as GOLD stage II in the results | 1.8 g | 90 days | 12 |
| N-acetylcysteine reduces cocaine-seeking behavior and anterior cingulate glutamate/glutamine levels among cocaine-dependent individuals 2021 · NAC condition · Adults aged 18–55 years with cocaine dependence | 1.8 g | 7 days | 12 |
| Relationship between S-adenosylmethionine, S-adenosylhomocysteine, asymmetric dimethylarginine, and endothelial function in healthy human subjects during experimental hyper- and hypohomocysteinemia 2005 · N-acetylcysteine (NAC) · Healthy adults, mean age 29.1 years | 100 mg/kg | 1 day | 10 |
| A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis 2009 · 2800 mg NAC (high-dose) · Patients older than 16 years with cystic fibrosis and stable disease | 2.8 g | 12 weeks | 10 |
| Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double-blind placebo-controlled pilot study 2011 · NAC · Heavy smokers attempting to quit smoking | 3.6 g | 4 days | 10 |
| Thiol-based antioxidant supplementation alters human skeletal muscle signaling and attenuates its inflammatory response and recovery after intense eccentric exercise 2013 · N-acetylcysteine (NAC) · 10 men after muscle-damaging exercise | 20 mg/kg | 8 days | 10 |
| Influence of n-acetylcysteine maintenance on the pharmacodynamic effects of oral ethanol 2020 · 2.4 g/day n-acetylcysteine condition · Adults aged 21–55 with moderate to severe alcohol use disorder | 2.4 g | 5 days | 9 |
| Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus 2013 · NAC 1,200 mg twice daily · Adults with systemic lupus erythematosus; age range 20–67 years; predominantly women | 2.4 g | 90 days | 8 |
| Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus 2013 · NAC 2,400 mg twice daily · Adults with systemic lupus erythematosus; age range 20–67 years; predominantly women | 4.8 g | 90 days | 8 |
| Continuous oral N-acetylcysteine treatment and development of nitrate tolerance in patients with stable angina pectoris 1991 · ISDN + NAC · Patients with stable angina pectoris | 2.4 g | 8 days | 7 |
| The treatment of complex regional pain syndrome type I with free radical scavengers: a randomized controlled study 2003 · NAC group · Patients with complex regional pain syndrome type I (CRPS I) | 1.8 g | 17 weeks | — |
| Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients 2008 · N-acetyl-cysteine (NAC) · Schizophrenia patients; age and sex not specified | 2 g | 60 days | — |
| N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial 2008 · N-acetyl cysteine (NAC) · Adults with chronic schizophrenia receiving maintenance antipsychotic medication | 2 g | 24 weeks | — |
| N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial 2008 · NAC · People with bipolar disorder in the maintenance phase | 2 g | 24 weeks | — |
| N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial 2012 · N-acetylcysteine group · Adults with treatment-refractory obsessive-compulsive disorder who had failed to respond to serotonin reuptake inhibitor treatment | 2.4 g | 12 weeks | — |
| Marijuana craving trajectories in an adolescent marijuana cessation pharmacotherapy trial 2013 · NAC · Treatment-seeking adolescents aged 15–21 with cannabis dependence | 2.4 g | 8 weeks | — |
| N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study 2015 · NAC-treated group · Outpatients with therapy-resistant tobacco use disorder receiving smoking-focused group behavioral therapy; age and sex not reported | 3 g | 12 weeks | — |
| The effects of N-Acetylcysteine on frontostriatal resting-state functional connectivity, withdrawal symptoms and smoking abstinence: A double-blind, placebo-controlled fMRI pilot study 2015 · N-Acetylcysteine · Generally healthy adult nicotine-dependent smokers who smoked at least 10 cigarettes per day and were not immediately interested in quitting | 2.4 g | 4 days | — |
| Oral N-acetylcysteine and exercise tolerance in mild chronic obstructive pulmonary disease 2017 · NAC · Adults with mild COPD | 1.8 g | 4 days | — |
| Use of N-acetylcysteine plus simethicone to improve mucosal visibility during upper GI endoscopy: a double-blind, randomized controlled trial 2018 · S + NAC 500 · Adults undergoing upper gastrointestinal endoscopy; mean age 49 years | 500 mg | 1 day | — |
| Use of N-acetylcysteine plus simethicone to improve mucosal visibility during upper GI endoscopy: a double-blind, randomized controlled trial 2018 · S + NAC 1000 · Adults undergoing upper gastrointestinal endoscopy; mean age 49 years | 1 g | 1 day | — |
| The effect of N-acetylcysteine and working memory training on cocaine use, craving and inhibition in regular cocaine users: correspondence of lab assessments and Ecological Momentary Assessment 2018 · N-acetylcysteine (NAC) · Men who regularly used cocaine | 2.4 g | 25 days | — |
| Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders 2018 · N-acetyl cysteine (NAC) · People with early-phase schizophrenia spectrum disorders; age and sex not specified | 3.6 g | 52 weeks | — |
| Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder 2020 · NAC · Adults aged 18–50 with cannabis dependence | 2.4 g | 12 weeks | — |
| Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study 2020 · high dose group · Breast cancer patients receiving adjuvant paclitaxel | 2.4 g | 12 weeks | — |
| Who responds to a multi-component treatment for cannabis use disorder? Using multivariable and machine learning models to classify treatment responders and non-responders 2023 · N-acetylcysteine (NAC) · Adults aged 18–50 with cannabis use disorder | 2.4 g | 12 weeks | — |
| N acetylcysteine in the treatment of alcohol use disorder: a randomized, double-blind, placebo-controlled trial 2023 · NAC · Participants with alcohol use disorder; age and sex not specified | 2.4 g | 4 weeks | — |
| Impact of Treatment with Antioxidants as an Adjuvant to Standard Therapy in Patients with Septic Shock: Analysis of the Correlation between Cytokine Storm and Oxidative Stress and Therapeutic Effects 2023 · Group 3 (NAC) · Adults over 18 years of any gender with septic shock | 2.4 g | 5 days | — |
| Lower rate of preeclampsia after antioxidant supplementation in pregnant women with low antioxidant status 2006 · supplementation group · Pregnant women screened positive for low antioxidant status at 8 to 12 weeks of gestation | 200 mg | — | 29 |
| Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance 2017 · Group A · Adults with chronic hepatitis C receiving pegylated interferon-α-2b and ribavirin | 1.8 g | 1 year | 30 |
| Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance 2017 · Group B · Adults with chronic hepatitis C receiving pegylated interferon-α-2b and ribavirin | 1.8 g | 1 year | 30 |
| Mechanical Ventilation Antioxidant Trial 2015 · vitamin C plus vitamin E plus N-acetylcysteine · critically ill adults requiring mechanical ventilation | 1.2 g | — | — |
| N-acetylcysteine potentiates the antihypertensive effect of ACE inhibitors in hypertensive patients 2002 · ACEI + NAC · Smoker adults aged 69 ± 5 years with hypertension, more than 10 years of smoking and more than 10 cigarettes daily | 1.8 g | 3 weeks | 18 |
| Relative bioavailability of generic and branded acetylcysteine effervescent tablets: A single-dose, open-label, randomized-sequence, two-period crossover study in fasting healthy Chinese male volunteers 2010 · Acetylcysteine crossover phase (test and reference formulations) · Healthy Chinese male nonsmokers aged 18–40 years with BMI 19–25 kg/m² | 600 mg | 1 day | 24 |
| The administration of N-acetylcysteine reduces oxidative stress and regulates glutathione metabolism in the blood cells of workers exposed to lead 2013 · NAC 2 × 400 mg per day · Healthy male workers exposed to lead | 800 mg | 12 weeks | — |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · NF group, 3-month blinded trial · Community-dwelling adults aged 18–86 years, both sexes, without dementia or clinical memory difficulties | 600 mg | 90 days | 59 |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · Open-label NF group, separate 6-month trial · Community-dwelling adults, both sexes, without dementia or clinical memory difficulties | 600 mg | 26 weeks | 38 |
| Effects of Macuprev(®) Supplementation in Age-Related Macular Degeneration: A Double-Blind Randomized Morpho-Functional Study Along 6 Months of Follow-Up 2019 · AMD-M group · Adults with intermediate age-related macular degeneration; 9 male and 21 female enrolled overall, mean age 69.32 years | 140 mg | 26 weeks | 15 |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · NF group, 2-week blinded trial · Community-dwelling adults, both sexes, without dementia or clinical memory difficulties | 600 mg | 2 weeks | — |
| Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease 2001 · NAC group · Adults with stable chronic obstructive pulmonary disease (COPD) | 600 mg | 1 year | 22 |
| The effect of N-acetylcysteine supplementation upon viral load, CD4, CD8, total lymphocyte count and hematocrit in individuals undergoing antiretroviral treatment 2002 · NAC group · Adults with HIV-1 infection undergoing antiretroviral treatment | 600 mg | 180 days | 10 |
| N-acetylcysteine in handgrip exercise: plasma thiols and adverse reactions 2011 · Arm 1, 300 mg NAC capsule dose · Healthy adults aged 21–55 years, both sexes, without acute illness or chronic disease | 600 mg | 1 day | 10 |
| Effects of folic acid and N-acetylcysteine on plasma homocysteine levels and endothelial function in patients with coronary artery disease 2007 · NAC · Patients with hyperhomocysteinaemia and coronary artery disease; age and sex not reported | 600 mg | 8 weeks | — |
| Effect of N-acetyl-cysteine and hyperoxia on erythropoietin production 2011 · NAC group · Healthy volunteers; age and sex not specified | 600 mg | 1 day | — |
| Effect of N-acetylcysteine administration on the expression and activities of antioxidant enzymes and the malondialdehyde level in the blood of lead-exposed workers 2014 · NAC 800 mg/day · Lead-exposed workers; age and sex not specified | 800 mg | 12 weeks | — |
| Effect of N-acetylcysteine administration on homocysteine level, oxidative damage to proteins, and levels of iron (Fe) and Fe-related proteins in lead-exposed workers 2016 · 2 × 400 mg NAC group · Male employees exposed to lead through their work | 800 mg | 12 weeks | — |
| Effect of N-acetyl cysteine in children with metabolic dysfunction-associated steatotic liver disease-A pilot study 2024 · 600 mg NAC/day · Children with obesity and biopsy-confirmed MASLD; mean age 13.6 ± 2.8 years | 600 mg | 16 weeks | — |
| Correlation of plasma lipidomic profiles with cardiometabolic disease in transfusion-dependent thalassemia patients with six-month N-acetylcysteine intervention: A prospective cohort study 2025 · intervention group · Thai patients with transfusion-dependent thalassemia; age and sex not reported | 600 mg | 26 weeks | — |
| Phase I/pharmacodynamic study of N-acetylcysteine/oltipraz in smokers: early termination due to excessive toxicity 2001 · Arm C · Healthy volunteer smokers | 1.2 g | 12 weeks | 9 |
| N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial 2012 · NAC Dose 1 (600 mg twice daily) · Adults aged 25–64 with clinically stable systemic lupus erythematosus | 1.2 g | 90 days | 9 |
| Phase I/pharmacodynamic study of N-acetylcysteine/oltipraz in smokers: early termination due to excessive toxicity 2001 · Arm A · Healthy volunteer smokers | 1.2 g | 12 weeks | 6 |
| Phase I/pharmacodynamic study of N-acetylcysteine/oltipraz in smokers: early termination due to excessive toxicity 2001 · Arm B · Healthy volunteer smokers | 1.2 g | 12 weeks | 4 |
| Plasma glutathione of HIV⁺ patients responded positively and differently to dietary supplementation with cysteine or glutamine 2012 · N-acetylcysteine (NAC) supplementation · Treated patients with HIV and healthy controls; ages 20–59 years, men and women | 1 g | 7 days | — |
| The administration of N-acetylcysteine reduces oxidative stress and regulates glutathione metabolism in the blood cells of workers exposed to lead 2013 · NAC 2 × 200 mg per day · Healthy male workers exposed to lead | 400 mg | 12 weeks | — |
| Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial 2003 · acetylcysteine · Chinese adults, mean age 68 years, with stable moderate renal insufficiency undergoing elective coronary angiography with or without intervention | 1.2 g | 2 days | 102 |
| Efficacy and safety of mesenchymal stem cell in Chinese patients with chronic renal failure: A pilot study in Shandong province, China 2021 · NACys · Chinese patients with chronic renal failure and eGFR below 60 mL/min/1.73 m² | 1.2 g | 8 weeks | 100 |
| Acetylcysteine and contrast agent-associated nephrotoxicity 2002 · group A · Patients with impaired renal function undergoing coronary and/or peripheral angiography and/or angioplasty | 1.2 g | — | 92 |
| N-Acetylcysteine effects on transforming growth factor-β and tumor necrosis factor-α serum levels as pro-fibrotic and inflammatory biomarkers in patients following ST-segment elevation myocardial infarction 2013 · NAC group · Adults aged 40–92 with ST-segment elevation myocardial infarction (STEMI) | 1.2 g | 3 days | 50 |
| N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia: A randomized controlled trial 2018 · NAC group · Adults aged 18–69 with bacterial community-acquired pneumonia, PSI class I–III | 1.2 g | 10 days | 37 |
| Efficacy Of N-Acetyl-Cysteine as Adjuvant Therapy for Diabetic Foot Osteomyelitis: An Open-Label Randomized Controlled Trial 2025 · NAC group · Adults aged 18 years or older with Wagner grade III or IV diabetic foot osteomyelitis and PEDIS score ≥7 | 1.2 g | 2 weeks | 25 |
| Comparative Study to Evaluate the Effect of Low-Protein Diet Supplementation with Taurine and N-Acetylcysteine, N-Acetylcysteine and Pyridoxamine Dihydrochloride in Preventing the Progression of Chronic Renal Failure in Patients with Non-Diabetic Kidney Disease 2022 · NP (NAC + pyridoxamine dihydrochloride) arm · Adults with non-diabetic chronic renal failure, GFR >15 and <60 ml/min/1.73 m², receiving standard care | 600 mg | 26 weeks | 24 |
| A Pilot Study to Evaluate the Effects of Oral N-Acetyl Cysteine on Inflammatory and Oxidative Stress Biomarkers in Rheumatoid Arthritis 2019 · NAC group · Patients with rheumatoid arthritis | 1.2 g | 12 weeks | 23 |
| Effects of N-acetylcysteine on oxidative stress biomarkers, depression, and anxiety symptoms in patients with multiple sclerosis 2023 · NAC group · Adults aged 18–60 with clinically definite relapsing-remitting multiple sclerosis and mild-to-moderate anxiety and depression symptoms | 1.2 g | 8 weeks | 21 |
| Effects of oral administration of N-acetyl-L-cysteine: a multi-biomarker study in smokers 2002 · NAC group · Healthy smoking volunteers; age and sex not reported | 1.2 g | 26 weeks | 20 |
| Usefulness of Antioxidants as Adjuvant Therapy for Septic Shock: A Randomized Clinical Trial 2020 · NAC · Adults of either sex with septic shock | 1.2 g | 5 days | 20 |
| Adjunct N-Acetylcysteine Treatment in Hospitalized Patients With HIV-Associated Tuberculosis Dampens the Oxidative Stress in Peripheral Blood: Results From the RIPENACTB Study Trial 2020 · RIPENAC (NAC group) · Adults aged 18 years or older, both sexes, hospitalized with HIV and confirmed pulmonary tuberculosis | 1.2 g | 8 weeks | 18 |
| Effect of oral N-acetylcysteine treatment on immune system in continuous ambulatory peritoneal dialysis patients 2012 · NAC group · Patients receiving continuous ambulatory peritoneal dialysis (CAPD); age and sex not specified | 1.2 g | 8 weeks | 16 |
| Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study 2010 · NAC · Adults on regular peritoneal dialysis; mean age 52 ± 13 years, 40% male | 1.2 g | 8 weeks | 15 |
| Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy 2010 · NAC group · Patients undergoing coronary angiography and/or percutaneous coronary intervention; chronic kidney disease was noted as a risk group, but was not stated as an eligibility requirement. | 1.41 g | — | 15 |
| N-Acetylcysteine inhibits platelet-monocyte conjugation in patients with type 2 diabetes with depleted intraplatelet glutathione: a randomised controlled trial 2012 · NAC · Men or post-menopausal women with type 2 diabetes; mean age 63.9 years | 1.2 g | 8 days | 14 |
| N-acetylcysteine in handgrip exercise: plasma thiols and adverse reactions 2011 · Arm 1, 600 mg NAC capsule dose · Healthy adults aged 21–55 years, both sexes, without acute illness or chronic disease | 1.2 g | 1 day | 10 |
| Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease 2010 · Healthy control subjects · Healthy adults | 1.2 g | 2 weeks | 7 |
| N-acetylcysteine reduces oxidative stress in sickle cell patients 2012 · 1,200 mg NAC group · Adults aged 20–47 with homozygous sickle cell anemia or HbSβ0-thalassemia | 1.2 g | 6 weeks | 6 |
| N-acetylcysteine reduces oxidative stress in sickle cell patients 2012 · 2,400 mg NAC group · Adults aged 20–47 with homozygous sickle cell anemia or HbSβ0-thalassemia | 1.2 g | 6 weeks | 4 |
| Long-term oral n-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD 2005 · group A · Adults with clinically stable COPD; mean age 65.93 years; 48 of 55 participants were male | 1.2 g | 60 days | — |
| N-acetylcysteine and fenoldopam protect the renal function of patients with chronic renal insufficiency undergoing cardiac surgery 2008 · Group 2 · Adults with chronic renal insufficiency (creatinine clearance ≤40 mL/min) undergoing cardiac surgery | 1.2 g | 3 days | — |
| N-acetylcysteine and fenoldopam protect the renal function of patients with chronic renal insufficiency undergoing cardiac surgery 2008 · Group 3 · Adults with chronic renal insufficiency (creatinine clearance ≤40 mL/min) undergoing cardiac surgery | 1.2 g | 3 days | — |
| The comparison of antioxidant and hematological properties of N-acetylcysteine and alpha-lipoic acid in physically active males 2009 · N-acetylcysteine (NAC) · Healthy, physically active men | 1.2 g | 8 days | — |
| Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease 2010 · 600 mg sustained-release NAC · Adults with end-stage renal disease | 1.2 g | 2 weeks | — |
| Dose dependent pharmacokinetics of N-acetylcysteine after oral dosing to man 1990 · 600 mg twice daily for 5 days · Healthy subjects; age and sex not reported | 1.2 g | 5 days | — |
| High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study 2013 · NAC · Adults aged 50–80 years with stable COPD | 1.2 g | 1 year | — |
| Effect of N-acetylcysteine administration on the expression and activities of antioxidant enzymes and the malondialdehyde level in the blood of lead-exposed workers 2014 · NAC 400 mg/day · Lead-exposed workers; age and sex not specified | 400 mg | 12 weeks | — |
| Effect of N-acetylcysteine administration on homocysteine level, oxidative damage to proteins, and levels of iron (Fe) and Fe-related proteins in lead-exposed workers 2016 · 2 × 200 mg NAC group · Male employees exposed to lead through their work | 400 mg | 12 weeks | — |
| N-acetylcysteine decreases urinary level of neutrophil gelatinase-associated lipocalin in deceased-donor renal transplant recipients: a randomized clinical trial 2018 · NAC · Deceased-donor kidney transplant recipients | 1.2 g | 5 days | — |
| Renal protective effect of N-acetylcysteine with stepwise ramping voltage against extracorporeal shock wave lithotripsy-induced renal injury: a prospective randomized trial 2020 · Group C · Adults with a single renal stone scheduled for extracorporeal shock wave lithotripsy (ESWL); age range and sex not reported | 1.2 g | 3 days | — |
| Renal protective effect of N-acetylcysteine with stepwise ramping voltage against extracorporeal shock wave lithotripsy-induced renal injury: a prospective randomized trial 2020 · Group D · Adults with a single renal stone scheduled for extracorporeal shock wave lithotripsy (ESWL); age range and sex not reported | 1.2 g | 3 days | — |
| N-Acetylcysteine Improves Inflammatory Response in COPD Patients by Regulating Th17/Treg Balance through Hypoxia Inducible Factor-1α Pathway 2021 · treatment group · Elderly patients with stable COPD, GOLD stage C or D | 1.2 g | 26 weeks | — |
| A study to evaluate the hepatoprotective effect of N- acetylcysteine on anti tuberculosis drug induced hepatotoxicity and quality of life 2023 · NAC group · Newly diagnosed patients with tuberculosis on first-line anti-tuberculosis treatment; age and sex not specified | 1.2 g | 4 weeks | — |
| Effect of N-acetyl cysteine in children with metabolic dysfunction-associated steatotic liver disease-A pilot study 2024 · 1200 mg NAC/day · Children with obesity and biopsy-confirmed MASLD; mean age 13.6 ± 2.8 years | 1.2 g | 16 weeks | — |
| The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa infection -- a pilot study 2015 · NAC group · Patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection | 2.4 g | 30 days | 11 |
| Endogenous plasma N-acetylcysteine and single dose oral bioavailability from two different formulations as determined by a new analytical method 1991 · first N-acetylcysteine formulation · adult volunteers; sex and age not reported | 200 mg | 1 day | 10 |
| Endogenous plasma N-acetylcysteine and single dose oral bioavailability from two different formulations as determined by a new analytical method 1991 · second N-acetylcysteine formulation · adult volunteers; sex and age not reported | 200 mg | 1 day | 10 |
| N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial 2012 · NAC Dose 2 (1,200 mg twice daily) · Adults aged 25–64 with clinically stable systemic lupus erythematosus | 2.4 g | 90 days | 9 |
| N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial 2012 · NAC Dose 3 (2,400 mg twice daily) · Adults aged 25–64 with clinically stable systemic lupus erythematosus | 4.8 g | 90 days | 9 |
| The administration of N-acetylcysteine reduces oxidative stress and regulates glutathione metabolism in the blood cells of workers exposed to lead 2013 · NAC 1 × 200 mg per day · Healthy male workers exposed to lead | 200 mg | 12 weeks | — |
| N-acetylcysteine modulates markers of oxidation, inflammation and infection in tuberculosis 2025 · NAC group · Adults with moderate or far-advanced pulmonary tuberculosis | 2.4 g | 120 days | — |
| Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial 2015 · NAC · Adults with at least moderate renal impairment undergoing cardiac catheterisation with or without percutaneous coronary intervention; mean age 68 years, 76% male | 2.4 g | 3 days | 185 |
| N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial 2009 · high-dose NAC · Patients with pre-existing renal impairment; age and sex not reported | 2.4 g | — | 106 |
| N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity 2004 · NAC group · Patients with chronic renal insufficiency referred for coronary and/or peripheral procedures; age and sex not reported | 2.4 g | — | 97 |
| A comparison between the effects of metformin and N-acetyl cysteine (NAC) on some metabolic and endocrine characteristics of women with polycystic ovary syndrome 2016 · NAC group · Women with diagnosed polycystic ovary syndrome (PCOS), without additional complications | 1.8 g | 24 weeks | 46 |
| Efficacy of N-acetylcysteine and motivational enhancement therapy for nicotine addiction: A randomized clinical trial 2025 · Intervention group · Adult male and female active smokers aged 18 or older who smoked at least 10 cigarettes daily for at least 6 months and intended to quit | 3.6 g | 12 weeks | 46 |
| New Approach Combination-Dosed Therapy for Nonalcoholic Steatohepatitis Versus Vitamin E: A Randomized Controlled Trial 2025 · group 2 · Patients with nonalcoholic steatohepatitis (NASH); age and sex not stated | 2.4 g | 26 weeks | 45 |
| Effects of N-acetyl cysteine and melatonin on early reperfusion injury in patients undergoing coronary artery bypass grafting: A randomized, open-labeled, placebo-controlled trial 2018 · N-acetyl cysteine group · Adults aged 39–76 with ischemic heart disease undergoing coronary artery bypass grafting; non-diabetic and with normal left ventricular function | 1.8 g | 2 days | 28 |
| The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography 2003 · NAC group · Patients with chronic renal failure and serum creatinine concentration above 10(6) micromol/L undergoing coronary angiography | 2 g | 2 days | 24 |
| Comparative Study to Evaluate the Effect of Low-Protein Diet Supplementation with Taurine and N-Acetylcysteine, N-Acetylcysteine and Pyridoxamine Dihydrochloride in Preventing the Progression of Chronic Renal Failure in Patients with Non-Diabetic Kidney Disease 2022 · NT (taurine + NAC) arm · Adults with non-diabetic chronic renal failure, GFR >15 and <60 ml/min/1.73 m², receiving standard care | 300 mg | 26 weeks | 23 |
| N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients: a randomized crossover magnetic resonance spectroscopy study 2012 · N-acetylcysteine condition · 8 cocaine-dependent patients and 14 healthy controls | 2.4 g | 1 day | 22 |
| Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: A comparative crossover study 2015 · NAC · Adults with metabolic-syndrome risk factors, including abdominal obesity and at least two additional risk factors; 5 men and 15 women overall | 200 mg | 3 weeks | 20 |
| Acute exposure to traffic-related air pollution alters antioxidant status in healthy adults 2020 · antioxidant · Healthy adults; age range and sex not specified; no chronic medical condition | 1.2 g | 7 days | 19 |
| Effect of Oral N-Acetylcysteine Supplementation on the Immunity System in Patients with Acute Myocardial Infarction 2019 · NAC group · Patients with ST-segment elevation acute myocardial infarction who received fibrinolytic therapy | 1.8 g | 3 days | 17 |
| N-acetylcysteine as an adjunctive treatment for smoking cessation: a randomized clinical trial 2020 · NAC group · Adults aged 18–65 of either sex with tobacco use disorder who continued smoking or had not reduced cigarettes after four weeks of smoking-cessation treatment | 1.8 g | 12 weeks | 17 |
| MicroRNA expression in response to controlled exposure to diesel exhaust: attenuation by the antioxidant N-acetylcysteine in a randomized crossover study 2013 · DE exposure plus N-acetylcysteine (DEN) · Adults aged 19–35 with stable physician-diagnosed asthma and/or airway hyperresponsiveness | 1.8 g | 6 days | 13 |
| N-acetylcysteine in handgrip exercise: plasma thiols and adverse reactions 2011 · Arm 2, 35 mg/kg NAC solution · Healthy adults aged 21–55 years, both sexes, without acute illness or chronic disease | 35 mg/kg | 1 day | 10 |
| N-acetylcysteine in handgrip exercise: plasma thiols and adverse reactions 2011 · Arm 2, 70 mg/kg NAC solution · Healthy adults aged 21–55 years, both sexes, without acute illness or chronic disease | 70 mg/kg | 1 day | 10 |
| N-acetylcysteine in handgrip exercise: plasma thiols and adverse reactions 2011 · Arm 2, 140 mg/kg NAC solution · Healthy adults aged 21–55 years, both sexes, without acute illness or chronic disease | 140 mg/kg | 1 day | 10 |
| N-acetylcysteine add-on treatment leads to an improvement of fornix white matter integrity in early psychosis: a double-blind randomized placebo-controlled trial 2018 · NAC · Men and women aged 18–38 with early-phase psychosis, with under 12 months of treatment for psychosis | 2.7 g | 26 weeks | 10 |
| A randomized, placebo-controlled pilot trial of N-acetylcysteine on oxidative stress and endothelial function in HIV-infected older adults receiving antiretroviral treatment 2016 · PharmaNAC 900mg twice daily · HIV-infected adults aged 50 years or older receiving virologically suppressive antiretroviral treatment | 1.8 g | 8 weeks | 9 |
| N-Acetyl-Cysteine Supplementation Improves Functional Connectivity Within the Cingulate Cortex in Early Psychosis: A Pilot Study 2019 · NAC arm · Patients with early psychosis; mean age 25 ± 6 years; men and women | 2.7 g | 26 weeks | 9 |
| Evaluation of high dose N- Acetylcysteine on airway inflammation and quality of life outcomes in adults with bronchiectasis: A randomised placebo-controlled pilot study 2024 · NAC · Adults with bronchiectasis; age range and sex not specified | 2.4 g | 6 weeks | 9 |
| The effects of N-acetyl cysteine on intrinsic functional connectivity and neural alcohol cue reactivity in treatment-seeking individuals with alcohol use disorder: a preliminary study 2025 · NAC · Adults aged 18–70 with DSM-5 alcohol use disorder who wanted to reduce or stop drinking | 2.4 g | 4 weeks | 9 |
| Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial 2012 · NAC condition · Adults aged 31–35 with schizophrenia; nine men and two women were recruited, and eight completed the study | 2 g | 8 weeks | 8 |
| A randomized, placebo-controlled pilot trial of N-acetylcysteine on oxidative stress and endothelial function in HIV-infected older adults receiving antiretroviral treatment 2016 · PharmaNAC 1800mg twice daily · HIV-infected adults aged 50 years or older receiving virologically suppressive antiretroviral treatment | 3.6 g | 8 weeks | 8 |
| [Assessment of lipid peroxidation in hyperbaric oxygen therapy: protective role of N-acetylcysteine] 1995 · group B · Patients receiving hyperbaric oxygen therapy; age and sex not specified | 1.8 g | — | 7 |
| Effect of cysteine derivatives administration in healthy men exposed to intense resistance exercise by evaluation of pro-antioxidant ratio 2007 · N-acetylcysteine (NAC) · Healthy men exposed to intense resistance exercise | 1.8 g | 3 days | — |
| Effects of sulphur-containing compounds on plasma redox status in muscle-damaging exercise 2009 · N-acetylcysteine (NAC) · Healthy, trained men | 1.8 g | 3 days | — |
| Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease 2010 · 1200 mg sustained-release NAC · Adults with end-stage renal disease | 2.4 g | 2 weeks | — |
| Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome 2011 · N-acetyl-cysteine (NAC) · Women with polycystic ovary syndrome (PCOS) | 1.8 g | 24 weeks | — |
| Effect of N-acetylcysteine administration on the expression and activities of antioxidant enzymes and the malondialdehyde level in the blood of lead-exposed workers 2014 · NAC 200 mg/day · Lead-exposed workers; age and sex not specified | 200 mg | 12 weeks | — |
| N-Acetylcysteine supplementation reduces oxidative stress and DNA damage in children with β-thalassemia 2014 · NAC group · Children with transfusion-dependent β-thalassemia | 10 mg/kg | 90 days | — |
| Effect of N-acetylcysteine administration on homocysteine level, oxidative damage to proteins, and levels of iron (Fe) and Fe-related proteins in lead-exposed workers 2016 · 1 × 200 mg NAC group · Male employees exposed to lead through their work | 200 mg | 12 weeks | — |
| Oral N-acetylcysteine reduces plasma homocysteine concentrations regardless of lipid or smoking status 2015 · NAC treatment, hyperlipidemic group (HYL) · Unmedicated middle-aged men with hyperlipidemia, stratified by smoking status | 1.8 g | 4 weeks | — |
| Oral N-acetylcysteine reduces plasma homocysteine concentrations regardless of lipid or smoking status 2015 · NAC treatment, normolipidemic group (NOL) · Unmedicated middle-aged normolipidemic men, stratified by smoking status | 1.8 g | 4 weeks | — |
| Effects of Selenium and/or N-Acetyl-Cysteine Supplementation on Nonthyroidal Illness Syndrome in Hemodialysis Patients: A Factorial Randomized Controlled Trial 2022 · group B · Hemodialysis patients with nonthyroidal illness syndrome; age and sex not specified | 600 mcg | 12 weeks | — |
| N-Acetylcysteine effects on glutathione and glutamate in schizophrenia: A preliminary MRS study 2022 · NAC group · Patients with schizophrenia or schizoaffective disorder | 2.4 g | 8 weeks | — |
| Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial 2015 · COM · Adults with at least moderate renal impairment undergoing cardiac catheterisation with or without percutaneous coronary intervention; mean age 68 years, 76% male | 2.4 g | 3 days | 181 |
| Effects of antioxidant supplementation on postprandial oxidative stress and endothelial dysfunction: a single-blind, 15-day clinical trial in patients with untreated type 2 diabetes, subjects with impaired glucose tolerance, and healthy controls 2005 · type 2 diabetes group · Adults with early-stage, untreated type 2 diabetes | 600 g | 15 days | 46 |
| Effects of antioxidant supplementation on postprandial oxidative stress and endothelial dysfunction: a single-blind, 15-day clinical trial in patients with untreated type 2 diabetes, subjects with impaired glucose tolerance, and healthy controls 2005 · impaired glucose tolerance group · Adults with impaired glucose tolerance | 600 g | 15 days | 46 |
| Effects of antioxidant supplementation on postprandial oxidative stress and endothelial dysfunction: a single-blind, 15-day clinical trial in patients with untreated type 2 diabetes, subjects with impaired glucose tolerance, and healthy controls 2005 · healthy control group · Healthy adults | 600 g | 15 days | 46 |
| Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial 2025 · Vit D 1000 + NAC (D1N) · Adults aged 65–82 years with vitamin D deficiency and BMI 25–35 kg/m² | 600 mg | 8 weeks | 22 |
| Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial 2025 · Vit D 5000 + NAC (D5N) · Adults aged 65–82 years with vitamin D deficiency and BMI 25–35 kg/m² | 600 mg | 8 weeks | 22 |
| Blood oxidative stress biomarkers in women: influence of oral contraception, exercise, and N-acetylcysteine 2022 · NAC trial · Recreationally active women aged 18–35 with natural regular menstrual cycles or using combined monophasic oral contraception | 105 mg/kg | 1 day | 20 |
| N-Acetylcysteine improves the disturbed thiol redox balance after methionine loading 2003 · Met+NAC group · Healthy volunteers; age and sex not reported | 1.8 g | 1 day | 18 |
| Sodium selenite and N-acetylcysteine in antiretroviral-naive HIV-1-infected patients: a randomized, controlled pilot study 1998 · Group A · Antiretroviral-naive adults with HIV infection at CDC'93 stages I and II | 1.8 g | 24 weeks | 13 |
| N-Acetyl Cysteine May Support Dopamine Neurons in Parkinson's Disease: Preliminary Clinical and Cell Line Data 2016 · NAC group · Adults aged 40–80 with Parkinson’s disease, Hoehn and Yahr stage I–III, on a stable medication regimen | 1.2 g | 90 days | 12 |
| Sodium selenite and N-acetylcysteine in antiretroviral-naive HIV-1-infected patients: a randomized, controlled pilot study 1998 · Group B · Antiretroviral-naive adults with HIV infection at CDC'93 stages I and II | 1.8 g | 12 weeks | 11 |
| Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress 2010 · N-acetylcysteine group · Adult hemodialysis patients | 1.2 g | 10 days | — |
| N-Acetyl Cysteine Is Associated With Dopaminergic Improvement in Parkinson's Disease 2019 · NAC group · Patients with Parkinson's disease | 1 g | 90 days | — |
| Effects of Selenium and/or N-Acetyl-Cysteine Supplementation on Nonthyroidal Illness Syndrome in Hemodialysis Patients: A Factorial Randomized Controlled Trial 2022 · group D · Hemodialysis patients with nonthyroidal illness syndrome; age and sex not specified | 600 mcg | 12 weeks | — |
| Gender differences among treatment-seeking adults with cannabis use disorder: Clinical profiles of women and men enrolled in the achieving cannabis cessation-evaluating N-acetylcysteine treatment (ACCENT) study 2017 · N-acetylcysteine group · Adults aged 18–50 who were treatment-seeking and met criteria for cannabis dependence | 2.4 g | 12 weeks | — |